precision medicine

Drug Combination Reduces Adverse Events and Need for Dose Reductions

06/02/2016

JCP Editors

The addition of plinabulin to non-small cell lung cancer (NSCLC) treatment with docetaxel may reduce the frequency of adverse events and help prevent dose reductions due to toxicity, according to an abstract at the...

The...

06/02/2016

Journal of Clinical Pathways

Research in Review

Review of EGFR Mutation-Positive NSCLC Drugs Identifies Optimal Treatments

06/02/2016

JCP Editors

A review of treatments for non-small cell lung cancer (NSCLC) that is epidermal growth factor receptor mutation positive (EGFR M+) has identified which therapies are the most effective at managing disease symptoms...

A...

06/02/2016

Journal of Clinical Pathways

Conference Coverage

American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

05/31/2016

Its once again time for the American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7, 2016; Chicago, IL), which will bring together more than 30,000 oncology professionals from around the world to...

Its...

05/31/2016

Journal of Clinical Pathways

Research in Review

Breast Cancer Biomarker of Chemotherapy Resistance Identified

05/26/2016

JCP Editors

Expression of methylation-controlled J protein (MCJ) may be an indicator of successful outcomes and reduced risk of relapse in patients with breast cancer, according to a recent study. Chemotherapy is a key part of...

...

05/26/2016

Journal of Clinical Pathways

Research in Review

Novel Biomarker Predicts Treatment Response in NSCLC

05/19/2016

JCP Editors

A study of SMARCA/BRG1 expression in patients with non-small cell lung (NSCLC) cancer has found that it is a significant indicator of prognosis and a novel predictive biomarker for increased sensitivity to...

A...

05/19/2016

Journal of Clinical Pathways

Research in Review

Post-Progression Nivolumab Treatment Effective for Patients With RCC

05/16/2016

JCP Editors

Patients with renal cell carcinoma may continue to benefit from treatment with nivolumab even after the disease has progressed, according a study published JAMA Oncology. Still a relatively new line of treatments,...

...

05/16/2016

Journal of Clinical Pathways

Research in Review

Adverse Event Linked to Everolimus Does Not Negatively Impact Survival

05/13/2016

JCP Editors

Incidence of a common adverse event should not be considered a hindrance to the administration of everolimus for patients with cancer, according to a recent study. Everolimus is an oral mammalian target of rapamycin...

...

05/13/2016

Journal of Clinical Pathways

Pharma Insights

Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?

05/06/2016

David Parker, PhD

Larry Blandford, PharmD—Column Editor

We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...

We are...

05/06/2016

Journal of Clinical Pathways

Research in Review

FACT-B Most Effective Health-Related Quality of Life Instrument for Breast Cancer

05/06/2016

JCP Editors

Results from a study evaluating different tools intended to measure patient-reported health-related quality of life (HRQoL) in patients with breast cancer suggest that the Functional Assessment of Cancer...

...

05/06/2016

Journal of Clinical Pathways

Research in Review

Hormone Therapy More Cost-Effective Than Chemotherapy for Patients With HR+/HER2- Metastatic Breast Cancer

05/06/2016

JCP Editors

A study of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer has found that treatment with first-line chemotherapy offers no survival...

...

05/06/2016

Journal of Clinical Pathways